A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele

Author： Andersson Marine L Eliasson Erik Lindh Jonatan D

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.7, 2012-05, pp. : 757-762

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

By Ragia Georgia Petridis Ioannis Tavridou Anna Christakidis Dimitrios Manolopoulos Vangelis G

Pharmacogenomics, Vol. 10, Iss. 11, 2009-11 ,pp. : 1781-1787

Future Medicine

Access to resources Recommend Favorite

Allele Frequency Distributions of the Drug Metabolizer Genes CYP2C9*2, CYP2C9*3, and CYP2C19*17 in the Buginese Population of Indonesia

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 4, 2014-12 ,pp. : 236-239

Bentham Science Publishers

Access to resources Recommend Favorite

Reduced cytochrome P450 (CYP) 2D6 activity may contribute to an interaction between tramadol and warfarin

Reactions Weekly, Vol. 1, Iss. 1017, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Warfarin: Haematuria in a patient with CYP2C9*3/*3 genotype: case report

Reactions Weekly, Vol. 1, Iss. 1318, 2010-01 ,pp. : 46-46

Adis International

Access to resources Recommend Favorite

Warfarin: CYP2C9 polymorphisms increase risk of bleeding events

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite